Thomas Kofoed, PhD

CEO and Co-founder of Alphalyse

With over 25 years of experience, Thomas Kofoed is a seasoned specialist in developing protein analyses and mass spectrometry methods for protein biologics development. He holds a PhD in Chemistry from the University of Southern Denmark and a degree in Business Administration.

He has been responsible for general management of Alphalyse since its inception in 2002. Previous positions include Head of Proteomics at ACE BioSciences, Associated Professor at Copenhagen University, and Senior Scientist at PNA Diagnostics.

Thomas has been a key driver in developing the industry's most robust and reproducible mass spectrometry-based protein impurity analysis method, which has recently been included in USP General Chapter 1132.1. He guided Alphalyse to become the first commercial laboratory in the world to receive approval for GMP-validated HCP analysis for release testing by the Danish Medicines Agency in 2022.

As a seasoned specialist on the topic of mass spectrometry and HCP analysis, Thomas has given invited talks at several industry meetings, including the BEBPA HCP conference in 2017, 2018, and 2021, ESAC in 2009 and 2017, MS-Öresund in 2011, the Bioprocessing Summit in 2023 and 2024, and many more.

Regulatory consequences of USP 1132.1

Article: Regulatory Consequences of New Protein-Impurity Guidelines

The industry is on the brink of a paradigm shift with the release of the USP <1132.1>
Beyond ELISA - is mass spectrometry the future of impurity analysis?

Article: Is mass spectrometry the future of impurity analysis?

3 CMC specialists talks about current & future applications of LC-MS for impurity analysis
Investigate polysorbate degrading HCPs

Poster: Sensitive MS-based lipase assay for mAb products

Sensitive MS-based MRM assay to detect polysorbate-degrading HCPs in mAb products
An Alphalyse employee works with an LC-MS instrument

Blog: Why is reproducible mass spectrometry challenging?

Robust and reproducible MS-based analysis is invaluable in many parts of CMC documentation
Process webinar

Webinar: #Rethink your HCP strategy

Monitor HCP clearance for expression systems without access to an ELISA kit
process-related impurities

Article: Monitoring process-related impurities in biologics

HCP control strategies used in regulatory license applications presented by case studies
mab webinar

Webinar: Why do we need orthogonal HCP analysis for mAbs?

How to investigate your mAb for potentially problematic HCPs < 1ppm
GMP validated HCP analysis using LC-MS

Webinar: Moving LC-MS analysis into a GMP environment

Controlling variability in HCP analysis by LC-MS and qualifying the data
Principles of SWATH LC-MS analysis

Webinar: The principles of mass spectrometry for HCP analysis

Host cell protein analysis assay using mass spectrometry
Analysis of HCPs in process samples by mass spectrometry

White paper: HCP analysis of downstream process samples by LC-MS

written by Rikke Lund, Ejvind Mortz, Thomas Kofoed et. al
Assessing and monitoring quality of therapeutic mAb products

Blog post: Assessing and monitoring quality of therapeutic mAb products

Advice on which analyses to conduct for proper mAb characterization
How to identify peaks observed by UV-HPLC in stability studies

Blog post: How to identify peaks observed by UV-HPLC in stability studies

How to set up a detection method distinguishing molecules by their molecular mass
extinction coefficient triple amino acid

Blog post: Why you need accurate concentration determination of protein standards

Ever questioned quantitative data from Bradford, Lowry, or BCA protein quantification assays?

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
Hidden
Hidden
Hidden
This field is for validation purposes and should be left unchanged.